Insulet Corporation (PODD)

Last Price:  

Company Description

INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $904.40M
Net Income (Most Recent Fiscal Year) $6.80M
PE Ratio (Current Year Earnings Estimate) 571.57
PE Ratio (Trailing 12 Months) 0.03M
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 20.00
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 43.36
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 306.37
Pre-Tax Margin (Trailing 12 Months) -3.33%
Net Margin (Trailing 12 Months) -3.06%
Return on Equity (Trailing 12 Months) 0.21%
Return on Assets (Trailing 12 Months) 0.06%
Current Ratio (Most Recent Fiscal Quarter) 5.87
Quick Ratio (Most Recent Fiscal Quarter) 4.95
Debt to Common Equity (Most Recent Fiscal Quarter) 2.69
Inventory Turnover (Trailing 12 Months) 2.06
Book Value per Share (Most Recent Fiscal Quarter) $9.16
Earnings per Share (Most Recent Fiscal Quarter) $0.10
Earnings per Share (Most Recent Fiscal Year) $0.10
Diluted Earnings per Share (Trailing 12 Months) $-0.46
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Common Shares Outstanding 68.87M
Free Float 68.19M
Market Capitalization $19.91B
Average Volume (Last 20 Days) 0.26M
Beta (Past 60 Months) 0.67
Percentage Held By Insiders (Latest Annual Proxy Report) 1.00%
Percentage Held By Institutions (Latest 13F Reports) 99.99%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%